PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
September 10, 2025Clinical Infectious Diseases

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness

View Full Paper
Ask AI
Bookmark
Share

Authors

ABAdarsh BhimrajYFYngve Falck‐YtterLBLindsey R. Baden

Discussion

Loading...

Member takes

Overview

Clinical practice guideline outlines new recommendations for treating severe COVID-19, indicating pre-exposure prophylaxis for at-risk individuals.

Key Points

  • The updated guidelines recommend using pemivibart for pre-exposure prophylaxis to prevent COVID-19 in at-risk patients.
  • Evidence from systematic literature reviews supports the use of vilobelimab for managing critical illness due to COVID-19.
  • The recommendations, based on the GRADE approach, emphasize the importance of tailored treatment strategies for severe or critical cases.
  • These focused updates aim to improve clinical outcomes for adults, children, and pregnant people suffering from COVID-19.

Cite This Study

Bhimraj et al. (2025) studied this question.

synapsesocial.com/papers/68c1ad6354b1d3bfb60e59b4https://doi.org/10.1093/cid/ciaf424
View Full Paper
Ask AI
Bookmark
Share